

## Cellnovo announces the registration of its *document de base* in the context of its planned IPO on the regulated market of Euronext in Paris

**Paris, France, March 2, 2015** – Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announces the registration of its *document de base* with the Autorité des Marchés Financiers (AMF), under number I.15-008 on February 27, 2015.

The registration of the *document de base* is the first step towards the Initial Public Offering of Cellnovo's shares on the regulated market of Euronext in Paris, subject to market conditions and regulatory prerequisites, in particular the AMF's visa on the prospectus to be prepared in respect of the proposed transaction.

### A medtech company specialising in the management of diabetes and with the necessary key assets to establish itself on the insulin pump market

Established in 2002 and based in France and the United Kingdom, Cellnovo is a company that manufactures and distributes a proprietary diabetes management system consisting of a patch (i.e. tubeless) pump, a touchscreen mobile handset/controller and secure access to an online clinical management tool.

Founded on the concept of e-health, Cellnovo's insulin patch pump represents a major breakthrough in the way diabetes is treated. Certain aspects of diabetes management still require an action from the patient (blood glucose monitoring and injection of insulin just before meals). The Cellnovo pump allows patients and healthcare professionals to monitor the patient's use of insulin, activity and food intake in real time and the patient's blood-glucose level. These are four key factors in the management of diabetes.

### The Cellnovo Pump: a revolution in the management of Type 1 diabetes

- **The first connected device for managing diabetes differently**
  - Cellnovo's insulin pump is discreet, compact, silent, tubeless, entirely connected and has intuitive features;
  - This pump is connected to a touchscreen mobile handset with an integrated blood-glucose meter, and all the information is directly accessible via a secure online portal;
  - Thanks to the automatic transmission of data (diffusion of insulin, physical activity, food, , etc.) and the possibility for the patient to measure at anytime its blood glucose level, the first connected insulin pump allows the user to be continually monitored to the benefit of all stakeholders: the patient is more independent and better manages his condition<sup>(1)</sup>, their family has real-time information about the patient's condition, clinicians can be more responsive and efficient, and paying agencies and health authorities can be assured of the quality of care provided, reduced risk of complications and lower costs.
- **Use of high-precision technology that has notably proven itself in the aerospace sector**
  - The pumping mechanism incorporated within the Cellnovo pump is based on the use of paraffin wax, a phase-change material, which enables the basal insulin to be administered extremely accurately and continuously throughout the day.



## The First Connected All-in-one Diabetes Management System

All in all, the major innovation of the Cellnovo insulin pump lies in its ability to manage diabetes simply and efficiently while reducing the constraints and risks associated with this illness. The current version of the Cellnovo System is patented and has obtained CE marking; furthermore, it complies with existing reimbursement schemes governing insulin pumps and their consumables.

### Insulin Pumps: a growing market with substantial potential in one of the most extensive global diseases in terms of prevalence and health expenditure

Cellnovo first and foremost addresses patients with Type 1 diabetes who require insulin on a daily basis, i.e. 3.5 million people in North America and major European countries alone. The pump market targeted by Cellnovo is extensive and well identified. It concerns more than 610,000 people in the aforementioned regions, i.e. a 2.2 billion dollar market<sup>(1)</sup>. This market has substantial growth potential, as on average only 17%<sup>(2)</sup> of people with Type 1 diabetes are currently using insulin pumps, the other patients still having to rely on multiple daily injections.

Furthermore, 9.2 million<sup>(3)</sup> patients with Type 2 diabetes also use insulin therapy. Half of these patients have poorly regulated diabetes, and having a Cellnovo Pump would be beneficial for their therapy. At the current time, 1% of them already use insulin pumps.

### A clearly-defined international expansion strategy

Cellnovo launched the marketing of its insulin pump in the United Kingdom and France in 2014 via a direct sales force. Its commercialisation will be extended to other European countries in 2015-2017, followed by the United States in 2017, via a network of distributors. By 2020, Cellnovo's target is for 45,000 patients to be equipped with its pump, or 75% of its installed production.

(1) *Renub research analysis, Insulin Pump Market and Forecast – Worldwide analysis, Janv. 2014*

(2) *Company estimates*

(3) *Société francophone de diabétologie, Sept. 2014*

**Availability of the *document de base*** – Cellnovo's *document de base* is available free of charge and upon request to Cellnovo Group SA (26-28 rue de Londres, 75009 Paris, France) and on the company's ([www.cellnovo.com](http://www.cellnovo.com)) and AMF's ([www.amf-france.org](http://www.amf-france.org)) websites.

**Risk factors** – Cellnovo draws the public's attention to Section 4 "Risk Factors" of the *document de base* registered with the AMF and more specifically on the 4.1.1 risks factors "Risks related to the development of the Company's products".

### About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. Certain aspects of diabetes management still require an action from the patient (blood glucose monitoring and injection of insulin just before meals). This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

Cellnovo aims to improve the quality of life of patients with type 1 diabetes and more generally all people living with insulin dependency, by using its technology to minimise the constraints and risks associated with this illness.

The current version of the system has already received CE Marking, is reimbursed in most countries and is already being marketed in France and the United Kingdom. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product's commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to cope with the expected high level of demand.

The insulin pump market is currently estimated to be worth around 2.2 billion dollars, and has substantial potential given that only 17% of the 3.5 million people with type 1 diabetes (in the US/Canada and main European countries) currently use a pump.

Based in France and the United Kingdom, Cellnovo has a 75-strong workforce.

For further information please visit [www.cellnovo.com](http://www.cellnovo.com)



## The First Connected All-in-one Diabetes Management System

Cellnovo  
Sophie Baratte  
[investors@cellnovo.com](mailto:investors@cellnovo.com)

NewCap  
Relations investisseurs  
Antoine Denry  
[cellnovo@newcap.fr](mailto:cellnovo@newcap.fr)  
+ 33 1 44 71 94 95

NewCap  
Relations Médias  
Nicolas Merigeau  
[cellnovo@newcap.fr](mailto:cellnovo@newcap.fr)  
+33 1 44 71 98 55

### Disclaimer

This press release and the information it contains does not, and will not, constitute a public offering to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Cellnovo in any jurisdiction, including the United States, Canada, Australia or Japan. No public offering can be made now or in the future without the prior approval by the French Financial Markets Authority (*Autorité des Marchés Financiers* or "AMF") of a prospectus that consists of the Base Document (*document de base*), which is the subject of this press release, and a Securities Note (*note d'opération*) subsequently submitted to the AMF. The publication or distribution of this communication may violate applicable laws and regulations in some jurisdictions. Therefore, persons in such countries and in countries in which this communication is broadcast, published or distributed must enquire about any local restrictions and comply with them.

### In particular:

Cellnovo securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Cellnovo does not intend to register any securities in the United States or to conduct a public offering of securities in the United States.

This communication is an advertisement and does not constitute a prospectus for the purposes of the Prospectus Directive (as defined below). A prospectus prepared pursuant to the Prospectus Directive may be published, which, as and when published, can be obtained in accordance with the Prospectus Directive.

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been taken or will be taken to offer securities to the public that requires the publication of a prospectus in any Relevant Member State other than France. Cellnovo securities may be offered in a Relevant Member State (other than France) only (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive); or (iii) in any other circumstances falling within Article 3(2) of the Prospectus Directive, *provided, that* no such offer of securities shall require Cellnovo to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expressions "public offering" and "offer to the public" in relation to any Cellnovo securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State. The expression "Prospectus Directive" means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) persons in the United Kingdom who have professional experience in matters related to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). Cellnovo securities will only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire Cellnovo securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this release or any of its contents.

All statements other than statements of historical fact included in this press release about future events and are subject to (i) change without notice and (ii) factors beyond the Cellnovo's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond Cellnovo's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.